Background
Circulating cell-free DNA
Diagnosis
cf-DNA | Year | Sample Type | NO. Patients | Targeted gene | Diagnosis | Prognosis | Response to therapy | Reference |
---|---|---|---|---|---|---|---|---|
DNA amount | 2015 | Serum | 36 | – | √ | – | – | [24] |
2014 | Plasma | 144 | Cyclophilin A | – | √ | – | [30] | |
2010 | Plasma | 164 | GAPDH, beta-actin | – | √ | – | [84] | |
Reversion mutation | 2017 | Plasma | 19 | BRCA1, BRCA2, TP53 | – | – | √ | [85] |
2017 | Plasma | 30 | BRCA1, BRCA2, TP53 | – | – | √ | [86] | |
Somatic mutation | 2014 | Plasma/serum | 1 | FGFR2-FAM76A | √ | – | – | [87] |
2012 | Plasma | 15 | KRAS, PIK3CA, H1047R | √ | √ | – | [36] | |
2008 | Plasma | 119 | p53 | √ | – | – | [88] | |
2005 | Plasma/serum | 69 | TP53 | – | √ | – | [89] | |
Aberrant methylation | 2017 | Serum | 114 | RUNX3, TFPI2, OPCML | √ | – | – | [90] |
2009 | Plasma | 33 | BRCA1, HIC1, PAX5, PGR-PROX, THBS1 | √ | – | – | [91] | |
2005 | Plasma | 51 | RASSF1A | √ | √ | – | [92] | |
2004 | Peritoneal fluids | 57 | Panel genes including: TIMP3, CDH1, APC, ESR1, BRCA1, MYOD1, GSTM3, TITF1 | √ | √ | – | [93] | |
Chromosomal abnormality | 2017 | Plasma | 57 | – | √ | – | – | [27] |
2002 | Serum | 38 | – | √ | √ | – | [94] | |
2001 | Serum | 30 | p53 | √ | √ | – | [95] |
Response to therapy
Identification of resistance mutations
Circulating tumor cells
Year | Sample | Sample timing | NO. Patients | Method of CTCs detection | CTCs Positive Rate | Targeted antigen/gene | Prognostic Significance | Reference |
---|---|---|---|---|---|---|---|---|
2017 | PB | Before surgery | 54 | Biotin-doped Ppydeposited microfluidic device | 98.1% | EpCAM, TROP-2, EGFR, vimentin, and N-cadherin | PFS | [96] |
2016 | PB | Before surgery | 56 | Size-dependent seperation | 58% | Gene panel including: EpCAM, MUC1, MUC16, CK18, 19, ERCC1 | NR | [59] |
2014 | PB | Before surgery | 80 | RT-PCR | 47.5% | MAGE-As | OS, PFS | [97] |
2013 | BM | Intra-operative period | 456 | ICC | 27% | A-45B/B3 | PFS | [98] |
2011 | PB | Before 2nd line chemotherapy | 216 | CellSearch® | 14.4% | EpCAM, CK, CD45 | OS, PFS | [57] |
2011 | PB | Before surgery | 86 | RT-PCR | 19% | EpCAM, MUC1, HER2 | OS | [99] |
2009 | PB | Before surgery | 71 | ICC | 60.6% | EpCAM, ESA, CK | PFS | [54] |
2009 | BM | Intra-operative period | 112 | ICC | 25% | A-45B/B3 | PFS | [100] |
2008 | PM | Before surgery | 20 | Density gradient/flow cytometry | 90% | Folate-AlexaFluor 488 DUPA-FITC | NS | [101] |
2007 | PB/BM | Before and after chemotherapy. | 57(PB)/46(BM) | ICC | 21%/54% | A-45B/B3, CK8, 18, 19 | OS, PFS | [102] |
2006 | PB | Before and after surgery | 24 | Immunomagnetic beads/RT-PCR | 75% | BER-EP4 | NS | [103] |
2003 | PB | Before surgery | 64 | ICC | 18.7% | CK7, 8, 18, 20, EGFR | NS | [104] |
2002 | PB/BM | After surgery and before adjuvant chemotherapy | 90(PB)/73(BM) | Immunomagnetic beads | 12%//21% | MOC-31 | NS | [105] |